Donald Steiner named 2009 recipient of major international diabetes prize

December 05, 2009

Donald F. Steiner, MD, the A. N. Pritzker Distinguished Service Professor Emeritus in the Departments of Medicine and Biochemistry and Molecular Biology at the University of Chicago, has been awarded the Manpei Suzuki Diabetes Prize for 2009, the foundation announced this week.

The prize, now two years old, is the largest for diabetes research. Inaugurated in 2008 to commemorate the 15th anniversary of the Manpei Suzuki Diabetes Foundation, it honors "those who have enlightened researchers in the field of diabetes around the world with their original and excellent scientific achievements." It includes a certificate of honor, a Japanese objet d'art and $150,000.

"I am highly honored," said Steiner. "It's humbling to be recognized by my peers and gratifying to receive an award of this stature for my life's work. I'm very grateful to my colleagues for the nomination, and to the Manpei Suzuki Diabetes Foundation for this distinction."

Steiner, a 1956 graduate of the University of Chicago School of Medicine, will receive the prize and present a commemorative lecture at the award ceremony on March 2, 2010.

The prize selection committee cited Steiner's outstanding achievements over many years of research. "He has greatly contributed to our increased understanding in the mechanism of insulin secretion and related disorders," the Foundation noted in their news release.

Steiner's best known contributions include: Steiner's contributions to understanding the biochemical nature of insulin production and the development of C-peptide measurement have had profound clinical implications. His work led to major improvements in purity and reduced immunogenicity of therapeutic insulin and ultimately to the development, via proinsulin, of recombinant human insulin for diabetes therapy. The human C-peptide assay has enhanced the diagnosis of insulin-secreting tumors of the pancreas and the evaluation of the success of islet transplants.

His discovery of proinsulin also paved the way to understanding how many other peptide hormones and neuropeptides in the brain and endocrine system are made and similarly processed to active peptide hormones and/or neurotransmitters.

The discovery of proinsulin was "a landmark," said Steiner's colleague, Graeme Bell, PhD, Louis Block Distinguished Service Professor at the University and an authority on the genetics of diabetes. "As the first prohormone, it launched inquiry into how secretory proteins are manufactured and processed in cells. It was also a key finding for the manufacture of synthetic human insulin used therapeutically today. Steiner's studies have had a profound and fundamental impact on the understanding of human health, disease and diabetes in particular."
-end-
The Manpei Suzuki Diabetes Foundation promotes research in the field of diabetology by encouraging young researchers through international contacts. The Foundation aims further science and technology and the improvement of the health and welfare of all people.

University of Chicago Medical Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.